focus -WSS

focus

author：entertainment 2025-10-01 18:33:03 - browse：382

There are a lot of reasons why updated data on Pfizer’s Lorbrena, a treatment for non-small cell lung cancer, might not seem to be a big deal. The results are an update on the clinical trial that resulted in the Food and Drug Administration granting Lorbrena full approval in 2001, so in a sense they are not even that new. For Pfizer investors, Lorbrena isn’t that big a deal, either. The medicine, for patients whose lung tumors have particular genetic mutations, generated only $575 million last year — an amount that is up 57% from the year prior, but that still constitutes only 1% of the drug giant’s annual sales.

But there is one number that makes the Lorbrena data quite eye-catching: In the updated data, the daily pill decreased the risk that cancer would progress or that a patient would die by 81% over five years.

That’s a stunning number, especially when one considers that Lorbrena was not being compared to an inert placebo but to Xalkori, another Pfizer targeted cancer drug.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Affirmative action in medical school literally saved lives
Next article： Research misconduct: Proposed new rules face resistance

WSS

Be careful with at

Biden administration begins canceling student loan debt for 804,000 borrowers

Illinois Supreme Court finds assault weapons ban constitutional

YouTube cracks down on misinformation on cancer treatment

FDA clears AI tool for detecting skin cancer

Elizabeth Holmes banned from government health programs

explore

focus

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

explore

Dobbs anniversary: the lost opportunity of abortion as health care

Megan Rapinoe shares emotional post following US Women's World Cup exit

State Dept. review finds Biden bears some blame for Afghanistan failures

The surgeon had a dilemma only a Nazi medical text could resolve

Peter Hotez and the public health issue of online harassment

Test for long Covid? Researchers find new clue in blood samples

As demand for Covid shots wanes, Moderna seeks its next success

Biotech venture capitalists face new demands from investors

Heart attack and stroke risk calculators need revising

After Optum profits sink, UnitedHealth makes changes

focus

Health AI: on the border between health care and tech

NIH director takes cautious approach to Biden drug pricing priority

Test for long Covid? Researchers find new clue in blood samples

Novo Nordisk touts Wegovy study, but still struggling with supply

NIH director takes cautious approach to Biden drug pricing priority

Research misconduct: Proposed new rules face resistance

focus

focus

entertainment

leisure time